



Post Authorisation Assessments

For details of post authorisation assessments prior to 1st January 2021,
please refer to the [EMA](#) website.

Cardalis 5 mg/40 mg Chewable Tablets for Dogs Vm 15052/5005

• 19 June 2024	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV).
• 06 September 2023	Submission of an updated Ph. Eur. CEP for an already approved manufacturer of an active substance.
• 28 April 2023	Change(s) in the SPC, labelling or package leaflet, to section 4.6 and 6 Adverse reactions.
• 19 October 2022	Change in the address of the MAH from Unit 3 Anglo Office Park, White Lion Road Amersham, Buckinghamshire HP7 9FB to Explorer House, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe, Buckinghamshire, HP10 0HH, United Kingdom.
• 08 July 2022	Additional quality control site for the finished product. Deletion of a non-significant specification parameter of an excipient. Minor changes to an approved test procedure for an excipient.